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Summary
Methotrexate (MTX) in low doses is used in the therapy of rheumatoid arthritis (RA). The aim 
of many studies is to identify factors predicting the outcome of treatment with methotrexate in 
rheumatoid arthritis. The action of MTX in RA is associated with the inhibition of inflammatory 
mediators synthesis. AIF-1 is a cytokine playing a role in chronic inflammatory processes. The 
levels of AIF-1 were significantly increased in synovial fluid from patients with RA. The aim of 
this study was to investigate the association between AIF1 gene polymorphisms (rs2269475:C>T, 
rs2736182:G>A, rs2259571:A>C) and response to treatment of RA patients with MTX. 
The study was carried out on 221 patients diagnosed with active rheumatoid arthritis, tre-
ated with MTX. Good responders were defined as patients who were receiving MTX and had 
a DAS28 of ≤2.4 at 6 months. 
With regard to the AIF1 rs2259571 polymorphism the remission of RA symptoms was observed 
in 52.99% of AA genotype carriers, in 45.25% of subjects with AC genotype, and in 32.84% with 
CC. The differences were statistically significant. CC vs AA p=0.03,OR 0.41, 95%CI (0.18-0.92). 
The results of this study suggest that the patients with the rs2259571 CC AIF1 genotype have 
a poorer response to therapy with MTX.
allograft inflammatory factor-1 • methotrexate • polymorphisms • rheumatoid arthritis
Authors’ Contribution:
 Study Design
 Data Collection
 Statistical Analysis
 Data Interpretation
 Manuscript Preparation
 Literature Search
 Funds Collection638
Postepy Hig Med Dosw (online), 2013; tom 67: 637-642
IntroductIon
Rheumatoid arthritis (RA) is a multifactorial disease and 
its treatment is mainly based on drugs modulating its 
course [14]. The optimal strategy in treatment of RA is 
to use effective disease-modifying antirheumatic drugs 
(DMARDs) in an early stage of disease in order to reduce 
disease activity and to prevent destructive arthropathy. 
This treatment goal is frequently achieved by methotrex-
ate (MTX) [4]. MTX is a foliate antagonist used in the ther-
apy of malignant disorders and low doses of methotrexate 
were introduced for the treatment of rheumatoid arthri-
tis because of its presumed antiproliferative, immunosup-
pressive and antiinflammatory properties [5,6]. MTX is 
however not effective in all patients and a significant pro-
portion of patients stop the therapy because of inefficacy 
or adverse events. Identification of genetic determinants 
of drug efficacy and toxicity will be valuable because they 
can be ascertained in the individual patient before ini-
tiation of therapy. Previous studies have revealed that 
therapy with MTX causes the decreased production of 
mediators which are involved in the inflammatory pro-
cess [7]. Allograft inflammatory factor-1 (AIF-1) is a cyto-
plasmic, inflammation-responsive protein that has been 
implicated in the regulation of inflammation. AIF-1 was 
first identified by Utans et al. [23] in 1995 in rat cardiac 
allografts with chronic rejection, in which the inflamma-
tory reaction played a key role. Autieri et al. [3] demon-
strated that expression of AIF-1 was correlated with the 
severity of cardiac rejection in clinical heart transplanta-
tion. Kimura et al. [13] identified AIF-1 in synovial tissues 
and fluid derived from RA patients. 
Several single nucleotide polymorphisms (SNPs) have 
been identified in the AIF1 gene [2,18,19,20]. In our pre-
vious studies we detected the association between AIF-1 
gene polymorphism and rheumatoid arthritis [19,20]. 
In this study we examined the association between 
rheumatoid arthritis and AIF1 gene polymorphisms 
(rs2269475:C>T, rs2736182:G>A and rs2259571:A>C) and 
response to treatment of RA patients with MTX.
Patients
The study was carried out on 221 RA patients (179 women, 
42 men) diagnosed with active rheumatoid arthritis, tre-
ated with MTX in a dose of 15 mg weekly and glucocorti-
costeroids. RA was diagnosed according to the criteria of 
the American College of Rheumatology (ACR).
Evaluation of clinical efficacy and toxicity
Good responders were defined as patients who were 
receiving MTX and had a DAS28 of ≤2.4 at 6 months of 
therapy (patients with remission of disease symptoms). 
Poor responders were defined as patients who were 
receiving MTX and had a DAS28 of >2.4 [8,12]. The study 
was approved by the local ethics committee and written 
informed consent was obtained from all subjects.
Genotyping
SNPs within the AIF1 gene were genotyped using 
Taqman genotyping assays. Genomic DNA was extrac-
ted from 200 µL of whole blood samples using GeneMA-
TRIX Quick Blood DNA Purification Kit (EURx, Poland). 
Pre-validated allelic discrimination TaqMan real-time 
PCR assays were used for detection of rs2269475:C>T, 
rs2736182:G>A and rs2259571:A>C SNPs. (respective assay 
IDs: C__15876778_10, C__16286882_10, and C___3274002_10, 
Applied Biosystems, USA). Fluorescence data were captu-
red using the 7500 FAST Real-Time PCR System (Applied 
Biosystems, USA), after 40 cycles of PCR. 
Statistical analysis
Chi-squared or Fisher’s exact test was used for qualita-
tive variables, while the Mann-Whitney test was used for 
the quantitative ones. P-value < 0.05 was considered sta-
tistically significant.
results
The efficacy of RA therapy with MTX is presented in 
table 1. Under MTX therapy remission of RA symptoms 
was achieved in 45.63% of AIF1 rs2269475 CC genotype 
carriers, in 46.77% of subjects with CT genotype and in 
60.00% of patients with TT genotype. The differences 
were not statistically significant (table 1).
The remission of RA symptoms was observed in 46.33% 
of AIF1 rs2736182 GG genotype carriers, and in 66.67% 
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RA. As shown in table 2 there were no statistically signi-
ficant associations between AIF-1 gene polymorphisms 
and clinical parameters of RA (table 2).
dIscussIon
AIF-1 is a cytokine playing an important role in chronic 
inflammatory processes, especially involving macropha-
ges. AIF-1 can affect macrophage functional state [16]. 
Immunohistochemical staining showed that this pro-
tein was strongly expressed in infiltrating mononuclear 
cells and synovial fibroblasts in RA compared with oste-
oarthritis. It was also demonstrated that AIF-1 induced 
proliferation of cultured synovial cells in a dose-depen-
dent manner and increased IL-6 production in synovial 
fibroblasts and peripheral blood mononuclear cells [13]. 
Macrophages stimulated with AIF-1 produced significan-
of subjects with GA genotype. The differences were not 
statistically significant. 
With regard to the AIF1 rs2259571 polymorphism the 
remission of RA symptoms was observed in 52.99% of AA 
genotype carriers in 45.25% of subjects with AC geno-
type and in 32.84% with CC. The differences were sta-
tistically significant. CC vs AA p=0.03 OR 0.41 95% CI 
(0.18-0.92) (table 1).
The remission of RA symptoms was achieved in 50.8% of 
A allele carriers and in 47.4% of patients with C allele. 
The differences were statistically significant; p=0.04 OR 
0.66, 95% CI (0.45-0.97) (table 1).
Additionally we analyzed the association between AIF-1 
gene polymorphisms and selected clinical parameters of 
Table 1. The associations between AIF-1 gene polymorphisms and response to treatment of RA patients after 6 months of MTX therapy
Patients with disease 
remission
N=103
Patients with active 
disease
N=118
p-valuea OR (95% CI)
n % n %
AIF1 rs2269475 
genotype
CC 68 45.63 81 54.37 TT+CT vs CC 0.77 0.89 (0.50-1.56)
CT 29 46.77 33 53.23 TT vs CT+CC 0.52 1.76 (0.48-6.43)
TT 6 60.00 4 40.00 TT vs CC 0.52 1.79 (0.48-6.59)
AIF1 rs2269475 
allele
C 165 45.80 195 54.20
T 41 50.00 41 50.00 T vs C 0.54 0.84 (0.52-1.37)
AIF1 rs2736182
genotype
GG 101 46.33 117 53.66 AA+GA vs GG 0.6 2.32 (0.21-25.93)
GA 2 66.67 1 33.33 AA vs GA+GG 1.0 -
AA 0 0.00 0 0.00 AA vs GG 1.0 -
AIF1 rs2736182
allele
G 204 46.5 235 53.5
A 2 66.7 1 33.3 A vs G 0.6 2.30 (0.21-25.59)
AIF1 rs2259571
genotype
AA 42 52.99 37 47.01 CC+AC vs AA 0.16 0.66 (0.38-1.15)
AC 49 45.25 55 54.75 CC vs AC+AA 0.049 0.47 (0.22-0.98)
CC 12 32.84 26 67.16 CC vs AA 0.03 0.41 (0.18-0.92)
AIF1 rs2259571
allele
A 133 50.80 129 49.20
C 73 47.40 107 52.60 C vs A 0.04 0.66 (0.45-0.97)
a Fisher exact test 640
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bits production of proinflammatory cytokines inclu-
ding TNF-α, IL-6 and IL- 1, which are important in the 
inflammatory process in RA [26].
So far AIF-1 gene polymorphisms have not been widely 
investigated. In our previous reports we described the 
association of the AIF1 rs2269475 T allele with increased 
risk of RA development as well as the rs2259571 CC geno-
type with active form of RA [19,20]. The significant role 
of AIF-1 and AIF-1 gene polymorphisms in RA pathoge-
nesis was also confirmed by Harney et al., who studied 
the AIF-1 gene rs2259571 and rs2269475 polymorphisms 
in RA patients [9].
The results of this study suggest that the patients with 
the rs2259571 CC AIF1 genotype have a poorer response 
to therapy with MTX. The reasons for this association 
may be composed. The worse response to therapy in 
these patients is probably due to increased disease acti-
vity before therapy. However, studies examining disease 
activity as a predictor of MTX response are inconsi-
stent, with some studies suggesting that patients with 
low disease activity are less likely to respond to therapy 
[1,21,22,25]. Nevertheless, in a study published by Hoek-
stra et al., patients with low disease activity at baseline 
were more likely to respond to treatment with MTX [11]. 
In this study we analyzed the association between AIF-1 
gene polymorphisms and the achievement of total 
tly increased amounts of IL-6, IL-10 and IL-12p40 com-
pared with control cells [24]. The above results suggest 
that AIF-1 plays an important role in cells of the mono-
cyte/macrophage lineage upon stimulation with inflam-
matory stimuli. It was shown that the macrophage cell 
line expressed a certain level of endogenous AIF-1 which 
could be enhanced by pro-inflammatory cytokines IL-1β 
or TNF-α [27]. The inflammatory mediators released by 
macrophages play an important role in the pathogenesis 
of RA and in the maintenance of inflammation in joints 
[15]. Moreover, the enhancement of macrophage apop-
tosis by MTX is an important mechanism of anti-inflam-
matory action in RA [17]. 
MTX is a drug commonly used in the therapy of RA. 
The mechanisms by which MTX at low doses modu-
lates inflammation in RA are still not fully expla-
ined. Many pharmacological mechanisms have been 
suggested, including inhibition of purine synthesis, 
promotion of adenosine release, inhibition of pro-
duction of proinflammatory cytokines, and suppres-
sion of lymphocyte proliferation [10]. MTX inhibits 
a number of important intracellular enzymes in 
the folate pathway including dihydrofolate reduc-
tase and thymidylate synthase. Inhibition of 5-ami-
noimidazole-4-carboxamide ribonucleotide (AICAR) 
transformylase results in accumulation of AICAR 
and increased adenosine release into the circulation. 
Extracellular adenosine increases cAMP, which inhi-
Table 2. Analysis of clinical parameters in relation to AIF1 genotypes 
Genotype
Age at onset [years] Rheumatoid factor positive Erosive RA Extra-articular manifestations
n Mean ± SD p a  (%) p b (%) p b (%) p b
AIF1 rs2269475 genotype
CC 149 48.71 ± 12.47
0.72
 70.5
0.92
59.7
0.89
18.8
0.42 CT 62 47.59 ± 13.67 72.6 62.9 19.3
TT 10 48.74 ± 12.92
 
70.0
 
60.0
 
30.0
AIF1 rs2736182 genotype
GG 218 47.64 ± 12.79
0.83
70.6
0.99
61.0
0.71
 
19.3
0.84
GA+AA 3 46.84 ± 14.97 100.0 66.7 33.3
AIF1 rs2259571 genotype
AA 79 47.59 ± 12.53
0.69
 
73.4
0.57
60.7
0.52
19.00
0.25 AC 104 46.75 ± 12.38  
69.2 62.5 15.4
CC 38 47.23 ± 13.78  
71.0 57.9 21.1
a Mann-Whitney test
b χ2 test641
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study we analyzed the association between selected RA 
parameters and AIF-1 genotypes. Our analysis did not 
reveal statistically significant associations. However, 
the mechanism by which AIF1 gene rs2259571 polymor-
phism modulates the response to MTX therapy in RA 
patients requires further investigations.
The study was supported by a grant of the Polish Mini-
stry of Science and Higher Education, no. NN 402 266 636.
remission in RA patients because in our previous report 
we revealed that the rs2259571 CC genotype was associa-
ted with active form of RA [19].
Previous studies examined various clinical factors pre-
disposing to disease remission in RA patients treated 
with MTX. To analyze whether AIF1 gene rs2259571 
polymorphism is associated with response to MTX the-
rapy independently of clinical RA parameters, in this 
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